We are analyzing https://link.springer.com/article/10.1007/s00262-021-02887-7.

Title:
Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy | Cancer Immunology, Immunotherapy
Description:
Cancer immunotherapy represents a potential treatment approach through non-specific and specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential modality of immunotherapy that depends on harvesting T cells from the tumor-bearing host, activating them in vitro and infusing them back to the same host. Several cytokines, in particular IL-2, IL-7 and IL-15, have been used to enhance survival T cells in vitro. Although effective, conditioning of T cells in vitro with these cytokines requires long-term culture which results in the loss of expression of their trafficking receptors mainly CD62L. It also results in exhaustion of the activated T cells and reduction in their functions upon adoptive transfer in vivo. Our recent studies and those of other groups showed that brief (3 days) conditioning of CD8+ T cells by IL-12 in vitro can result in enhancing function of tumor-reactive CD8+ T cells. Adoptive transfer of these IL-12-conditioned CD8+ T cells into tumor-bearing mice, preconditioned with cyclophosphamide, 1 day before ACT, induced tumor eradication that was associated with generation of tumor-specific memory response. In this review, we summarize studies that indicated to the superiority of IL-12 as a potential cytokine for conditioning T cells for ACT. In addition, we discuss some of the cellular and molecular mechanisms that govern how IL-12 programs CD8+ T cells to enhance their functionality especially in vitro and its implication in combination with other ACT modalities, opening a avenue for the clinical application of this cytokine.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,150,568 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, pubmed, google, scholar, cas, cells, cancer, interleukin, immunol, cell, adoptive, immunotherapy, therapy, internet, cytokine, antitumor, central, gene, vitro, salem, human, res, immunity, ther, conditioning, vivo, tumor, receptor, lymphocytes, activity, med, mice, clin, factor, exp, immunother, tanta, privacy, cookies, function, content, research, act, transfer, access, improves, cytotoxic, efficacy, patients, murine,

Topics {✒️}

month download article/chapter pre-established lung metastases interleukin-12-encapsulated biodegradable microspheres mohamed labib salem generating potent th1/tc1 tumor-specific memory response il-7 + il-15 increases yield t-cell adoptive immunotherapy tet-regulated il-12 expression superior anti-tumor activity ifn-γ-independent effects article cancer immunology il-12rbeta2-deficient mice full article pdf privacy choices/manage cookies article salem attia wy anti-schistosomasis vaccination adenovirus expressing interleukin-12 rubinstein mp situ tumor vaccination cell responses directed autologous fast dc enhancing adjuvant activity adoptive cell therapy nonviral polyethylenimine vector additional information publisher' il-12/23r beta 1 anti-tumor memory osteosarcoma lung metastases adoptive cell immunotherapy tumor-infiltrating lymphocytes effector/memory cells orthotopic tumor growth salem ml tumor-targeted cytokine cd4+ versus cd8+ leishmania major infection intestinal nematode infection anti-tumor activity cells mediate response aspergillus f16 allergen ifn-gamma receptor immunotherapy article adaptive immune responses zidan a-aa anti-tumor immunity interleukin-12 receptor system interferon gamma expression european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy
         description:Cancer immunotherapy represents a potential treatment approach through non-specific and specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential modality of immunotherapy that depends on harvesting T cells from the tumor-bearing host, activating them in vitro and infusing them back to the same host. Several cytokines, in particular IL-2, IL-7 and IL-15, have been used to enhance survival T cells in vitro. Although effective, conditioning of T cells in vitro with these cytokines requires long-term culture which results in the loss of expression of their trafficking receptors mainly CD62L. It also results in exhaustion of the activated T cells and reduction in their functions upon adoptive transfer in vivo. Our recent studies and those of other groups showed that brief (3 days) conditioning of CD8+ T cells by IL-12 in vitro can result in enhancing function of tumor-reactive CD8+ T cells. Adoptive transfer of these IL-12-conditioned CD8+ T cells into tumor-bearing mice, preconditioned with cyclophosphamide, 1 day before ACT, induced tumor eradication that was associated with generation of tumor-specific memory response. In this review, we summarize studies that indicated to the superiority of IL-12 as a potential cytokine for conditioning T cells for ACT. In addition, we discuss some of the cellular and molecular mechanisms that govern how IL-12 programs CD8+ T cells to enhance their functionality especially in vitro and its implication in combination with other ACT modalities, opening a avenue for the clinical application of this cytokine.
         datePublished:2021-05-08T00:00:00Z
         dateModified:2021-05-08T00:00:00Z
         pageStart:2751
         pageEnd:2759
         sameAs:https://doi.org/10.1007/s00262-021-02887-7
         keywords:
            Adoptive cell therapy
            Cancer
            Cyclophosphamide
            Cytokine
            IL-12
            Immunotherapy
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-021-02887-7/MediaObjects/262_2021_2887_Fig1_HTML.png
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:70
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mohamed Labib Salem
               url:http://orcid.org/0000-0003-0840-5291
               affiliation:
                     name:Tanta University
                     address:
                        name:Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt
                        type:PostalAddress
                     type:Organization
                     name:Tanta University
                     address:
                        name:Center of Excellence in Cancer Research (CECR), Tanta University, Tanta, Egypt
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Samar Salman
               affiliation:
                     name:Tanta University
                     address:
                        name:Department of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ibrahim O. Barnawi
               affiliation:
                     name:Taibah University
                     address:
                        name:Animal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy
      description:Cancer immunotherapy represents a potential treatment approach through non-specific and specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential modality of immunotherapy that depends on harvesting T cells from the tumor-bearing host, activating them in vitro and infusing them back to the same host. Several cytokines, in particular IL-2, IL-7 and IL-15, have been used to enhance survival T cells in vitro. Although effective, conditioning of T cells in vitro with these cytokines requires long-term culture which results in the loss of expression of their trafficking receptors mainly CD62L. It also results in exhaustion of the activated T cells and reduction in their functions upon adoptive transfer in vivo. Our recent studies and those of other groups showed that brief (3 days) conditioning of CD8+ T cells by IL-12 in vitro can result in enhancing function of tumor-reactive CD8+ T cells. Adoptive transfer of these IL-12-conditioned CD8+ T cells into tumor-bearing mice, preconditioned with cyclophosphamide, 1 day before ACT, induced tumor eradication that was associated with generation of tumor-specific memory response. In this review, we summarize studies that indicated to the superiority of IL-12 as a potential cytokine for conditioning T cells for ACT. In addition, we discuss some of the cellular and molecular mechanisms that govern how IL-12 programs CD8+ T cells to enhance their functionality especially in vitro and its implication in combination with other ACT modalities, opening a avenue for the clinical application of this cytokine.
      datePublished:2021-05-08T00:00:00Z
      dateModified:2021-05-08T00:00:00Z
      pageStart:2751
      pageEnd:2759
      sameAs:https://doi.org/10.1007/s00262-021-02887-7
      keywords:
         Adoptive cell therapy
         Cancer
         Cyclophosphamide
         Cytokine
         IL-12
         Immunotherapy
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-021-02887-7/MediaObjects/262_2021_2887_Fig1_HTML.png
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:70
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mohamed Labib Salem
            url:http://orcid.org/0000-0003-0840-5291
            affiliation:
                  name:Tanta University
                  address:
                     name:Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt
                     type:PostalAddress
                  type:Organization
                  name:Tanta University
                  address:
                     name:Center of Excellence in Cancer Research (CECR), Tanta University, Tanta, Egypt
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Samar Salman
            affiliation:
                  name:Tanta University
                  address:
                     name:Department of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ibrahim O. Barnawi
            affiliation:
                  name:Taibah University
                  address:
                     name:Animal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:70
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Tanta University
      address:
         name:Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt
         type:PostalAddress
      name:Tanta University
      address:
         name:Center of Excellence in Cancer Research (CECR), Tanta University, Tanta, Egypt
         type:PostalAddress
      name:Tanta University
      address:
         name:Department of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt
         type:PostalAddress
      name:Taibah University
      address:
         name:Animal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mohamed Labib Salem
      url:http://orcid.org/0000-0003-0840-5291
      affiliation:
            name:Tanta University
            address:
               name:Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt
               type:PostalAddress
            type:Organization
            name:Tanta University
            address:
               name:Center of Excellence in Cancer Research (CECR), Tanta University, Tanta, Egypt
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Samar Salman
      affiliation:
            name:Tanta University
            address:
               name:Department of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt
               type:PostalAddress
            type:Organization
      name:Ibrahim O. Barnawi
      affiliation:
            name:Taibah University
            address:
               name:Animal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt
      name:Center of Excellence in Cancer Research (CECR), Tanta University, Tanta, Egypt
      name:Department of Dermatology and VenereologyFaculty of MedicineTanta University Hospital, Tanta University, Tanta, Egypt
      name:Animal Section, Department of Biological Sciences, Faculty of Science, Taibah University, Medina, Saudi Arabia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(224)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.32s.

LINK . SPRINGER . COM {}